Toward this end, we strive to strengthen our competitiveness in key business fields through new drug development as we build corporate value through synergistic expansion.
We have a full-range of development programs spanning pre-clinical to phase 3 studies. This and our partnerships with more than 30 pharmaceutical firms and biotech ventures worldwide play a key role in our ongoing efforts to develop innovative new drug candidates and grow our pipeline.
We pursue strategic investments worldwide in companies with promising drug technologies and candidates. Recent notable investments include the establishment of JaguAhR Therapeutics, a Singapore-based joint venture with Aslan Pharmaceuticals focused on developing immuno-oncology therapeutics. We have also made an equity investment in Israel-based ProteKt Therapeutics, a developer of therapies for neurodegenerative conditions such as Alzheimer’s disease.
Our open innovation strategy drives our drug development pipeline. Profits generated by our pipeline are reinvested, creating a virtuous cycle that is enabling us to build a sustainable drug development model.
In addition to ethical drugs, we continue to expand our portfolio of consumer health products encompassing over-the-counter drugs, nutraceuticals, and personal care products.